NAS10028,142+0.54%S&P7,563+0.29%GOLD$3,929−1.02%BTC$77,513+1.09%VIX20.95−0.95%latest tape · as of 20:14 UTC
The Screen · Financials · Financial Data & Stock Exchanges
MCOMoody's Corporation
MCO · a US exchange · USD · Market cap $84.3B · 16,000 employees
Moody's Corporation, together with its subsidiaries, operates as an integrated risk assessment firm in the United States, the rest of the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
FAIL · Does not pass the screen
506.02 USD
Price as of 2 Nov 2026Daily close, not a live quote
Screened 2026-11-02 · the tape above runs as of 20:14 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price506.02 USD at the 2 Nov 2026 close
Our value readOvervalued vs our fair value, as of 2 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.33, read 2026-11-01
Ethical does not pass the values gate
Price506.02 USD
Fair value420.13
Ethical score10.0/100
Value readOvervaluedas of 2 Nov 2026
Our investment reviews on this name
2026-10-17Read Markup483.69+4.6% to today ✓Markdown gives way to Markup with results news in the headlines
2026-10-11Read Markdown468.70+8.0% to today Distribution gives way to Markdown
2026-07-02Read Distribution451.35+12.1% to today First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Moody's Corporation holds its Markup at $506.02. The statistical read favours the buyers, held for 7 days.
As held on the ledger · 2026-11-02
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 7 days
Price at the screen
$506.02
Valuation
30.48 trailing · 26.16 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.35
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Moody's does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-02. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when MCO's ethical verdict changes
Today MCO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 2 Nov 2026: it trades above our $420.13 fair value estimate, strong competitive moat, 0.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-02 screen. The gold marker is the market price at the same screen. The price runs 20.4% above the base estimate.
Third-party analyst targets: 21 covering, consensus Buy. The average target sits +11% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $420.13, with a range of $420.13 to $483.15, dated to the 2026-11-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Ratings Giant Trips Over Its Own Ethics Test
Every bond, loan and pension fund leans on Moody's stamps to judge risk. Yet the firm fails our ethical screen on business activity, so we pass regardless of the numbers.
The business itself looks solid, with 32 percent profit margins, 71 percent ROE and steady 8 percent revenue growth. Still, the shares sit at 27.4 times forward earnings, 19 percent above our fair value of 414.88 while the price is 510.86.
Analysts may cluster around a 550 target and call the moat strong, but the ethical fail is non-negotiable. That single line keeps us away. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day; it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MCO trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-28Markup$483.69+0.0%Entry 22
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 2% above its long-term trend line with momentum reading bullish. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536.
2026-10-21Markup$483.69+0.0%Entry 21
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-20Markup$483.69+0.0%Entry 20
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-19Markup$483.69+0.0%Entry 19
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markup$483.69+0.0%Entry 18
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-17Markup · changed$483.69+0.0%Entry 17
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-16Markdown$483.69+4.2%Entry 16
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-15Markdown$464.23+0.0%Entry 15
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-14Markdown$464.23-1.0%Entry 14
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-11Markdown · changed$468.70+0.0%Entry 13
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 6%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (20 analysts) rates it buy, with a mean price target of $536.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.